

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

RECEIVED  
SECRETARY OF THE SENATE  
PUBLIC RECORDS  
04 AUG 13 PM 5

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

**1. Registrant Name**

King & Spalding LLP

**2. Address**

Check if different than previously reported

1730 Pennsylvania Avenue, N.W.

**3. Principal Place of Business (if different from line 2)**

City: Washington

State/Zip (or Country): D.C. 20006

**4. Contact Name**

Theodore M. Hester

**Telephone**

202-626-2901

**5. Senate ID#**

21632-618

**7. Client Name**

Purdue Pharma L.P.

Self

**6. House ID#**

30750051

**TYPE OF REPORT** 8. Year 2004 Midyear (January 1 - June 30)  OR Year End (July 1 - Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  Termination Date \_\_\_\_\_

11. No Lobbying Ac

### INCOME OR EXPENSE - Complete Either Line 12 OR Line 13

**12. Lobbying Firms**

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more  \$ 20,000  
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

**13. Organizations**

**EXPENSE** relating to lobbying activities for this report period were:

Less than \$10,000

\$10,000 or more  \$ \_\_\_\_\_  
Expenses (nearest \$:

**14. REPORTING METHOD.** Check box to indicate accounting method. See instructions for description of

**Method A.** Reporting amounts using LDA definitio

**Method B.** Reporting amounts under section 6033(l) Internal Revenue Code

**Method C.** Reporting amounts under section 162(e) Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

LD-2 (REV. 6/98)

Page 1 of

Registrant Name King & Spalding LLP

Client Name Purdue Pharma L.P.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

Congressional investigations of OxyContin<sup>®</sup>. Prescription drug abuse and liability legislation, inclu 3870, the Prescription Drug Abuse Elimination Act.

17. House(s) of Congress and Federal agencies contacted  Check if None

U.S. House


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Theodore M. Hester	
William C. Talmadge	

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if Non

The foreign entity has an interest in the outcome of congressional investigations of OxyContin<sup>®</sup> and to combat prescription drug abuse.

Signature



August 13, 2004

Printed Name and Title Theodore M. Hester, Partner

LD-2 (REV. 6/98)

Page 2 of